Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Nexentis Technologies Inc's Competitiveness

Name: Nexentis Technologies Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Nexentis Technologies Inc (NXTS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/NXTS/competitors                    

                        https://api.csimarket.com/api/v1/companies/NXTS/relationships                    

                        https://api.csimarket.com/api/v1/companies/NXTS/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Nexentis Technologies Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Nexentis Technologies Inc	-	-	-	-
High-Confidence Competitors (2)				-
Similar-Size Competitors (7)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

NXTS Stock Performance relative to its Competitors

NXTS Competitors (weighted) Percent change over the selected range

Nexentis Technologies Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(0 of 1)

Similar-Size
(0 of 5)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Nexentis Technologies Inc	-94.50 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (1)	40.4%	63.2%
Similar-Size Competitors (5)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Nexentis Technologies Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

NXTS Stock Performance relative to High-Confidence Competitors

NXTS High-Confidence Competitors (equal-weighted, 5) Percent change over the selected range

NXTS Stock Performance relative to Similar-Size Competitors

NXTS Similar-Size Competitors (equal-weighted, 7) Percent change over the selected range

Nexentis Technologies Inc's Comment on Competition and Industry Peers

MitoCareX's compound STX-241 demonstrated strong biochemical inhibition of EGFR double mutant kinase activity and notable potency and selectivity against the C797S double mutant compared to clinical-stage competitor benchmarks. The company faces potential competition from clinical-stage entities developing similar technologies. MitoCareX seeks to protect its intellectual property through patents and trade secrets but acknowledges that competitors may independently develop similar technologies and that issued patents may not provide complete protection or competitive advantages. The competitive landscape includes numerous companies involved in renewable energy projects in Poland, Italy, and Germany, comprising both large global and local firms as well as smaller regional specialists. As of March 31, 2026, Solterra's market share in the renewable energy sector in these countries is not significant.

Competitor data is not yet available for Nexentis Technologies Inc.

Nexentis Technologies Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
Decco Worldwide	Named by the company	85%	2022 to 2026	3
Peroxychem	Named by the company	85%	2022 to 2026	3
United Phosphorous Ltd.	Named by the company	85%	2022 to 2026	3
Citrosol	Named by the company	85%	2022 to 2026	3
JBT	Named by the company	85%	2022 to 2026	3
Solvay S.A.	Named by the company	85%	2022 to 2026	3
Pace International	Named by the company	85%	2022 to 2026	3
Evonik Active Oxygens, LLC	Named by the company	85%	2022 to 2026	3
Solterra	Named by the company	85%	2022 to 2026	3
Xeda International	Named by the company	85%	2022 to 2026	3
Decco US Post-Harvest	Named by the company	85%	2022 to 2026	3
MitoCareX	Named by the company	85%	2022 to 2026	3
Sumitomo Chemical Company	Named by the company	85%	2022 to 2026	3
Agrofresh	Named by the company	85%	2022 to 2026	3
Fomesa	Named by the company	85%	2022 to 2026	3
Solvay	Named by the company	85%	2022 to 2026	3
Evonik Industries, AG	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Nexentis Technologies Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.